Medicaid

Investing in Health Equity | Why New Jersey Should Cover FDA-Approved Medications Through Medicaid

March 2026

New Jersey is at a critical inflection point. Like many states, obesity is on the rise in New Jersey, increasing by roughly…

Investing in Health Equity | Why New York Should Cover FDA-Approved Anti-Obesity Medications Through Medicaid

March 2026

New York faces an urgent challenge: without early, evidence-based intervention, today’s obesity crisis will become tomorrow’s diabetes, cardiovascular disease, or disability crisis…

Protect Maryland’s Future | Why Maryland’s Medical Assistance Program Should Cover FDA-Approved Anti-Obesity Medications

February 2026

Expanding Maryland Medicaid to ensure access to comprehensive, evidence-based obesity treatments would improve health outcomes, strengthen health equity, and help reduce long-term…

Investing in Health Equity | Why New Mexico Should Cover FDA-Approved Anti-Obesity Medications Through Medicaid

February 2026

New Mexico has an opportunity to take decisive action to support Medicaid coverage of FDA-approved AOMs.

OPINION: Pa.’s Medicaid rollback on obesity drugs is a crisis in slow motion

June 29, 2026

Health Equity Leaders Across Maryland Encouraged By General Assembly Passing SB 496, Urge Governor Moore to Sign Obesity Coverage Bill into Law

April 27, 2026

Santa Fe New Mexican: As obesity rises in New Mexico, advocates push for Medicaid to cover weight loss drugs

March 16, 2026